Request Demo
Recent blog posts
Latest Hotspot
8 min read
Retagliptin Phosphate/Metformin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Retagliptin Phosphate/Metformin: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Allisartan Isoproxil/Sacubitril Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Allisartan Isoproxil/Sacubitril: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Jaktinib Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Jaktinib Hydrochloride: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Fovinaciclib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Fovinaciclib: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Luvometinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Luvometinib: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Trastuzumab Rezetecan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Trastuzumab Rezetecan: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Indapamide/Allisartan Isoproxil Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Indapamide/Allisartan Isoproxil: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Albipagrastim alfa Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Albipagrastim alfa: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Fosrolapitant/Palonosetron Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Fosrolapitant/Palonosetron: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Deuterated enzalutamide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Deuterated enzalutamide: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Lerociclib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Lerociclib: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Famitinib Malate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
20 July 2026
Famitinib Malate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.